Achaogen Inc

Most Recent

  • uploads///joshua coleman  unsplash
    Company & Industry Overviews

    Why Achaogen Stock Fell Steeply Yesterday

    Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceuticals and Peers in April

    Of the 23 analysts covering BioMarin Pharmaceuticals in April 2018, eight analysts gave the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///BMRN
    Company & Industry Overviews

    Cash Flows and Valuation Metrics of BioMarin Pharmaceuticals

    BioMarin Pharmaceuticals’ (BMRN) cash, cash equivalents, and investments increased from $1.3 billion in fiscal 2016 to $1.7 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///cells _
    Company & Industry Overviews

    Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018

    Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.